Roche registers fenebrutinib MS extension study; CEACAM5 trial recruiting
Two Roche-sponsored studies on the clinical trials registry cover long-term fenebrutinib safety in multiple sclerosis and an early-phase RO7821657 cancer trial.
Two Roche-sponsored studies appear on the registry, one not yet recruiting and one already recruiting.
- Hoffmann-La Roche registered an open-label extension study of fenebrutinib in multiple sclerosis, listed as not yet recruiting with an estimated start of January 18, 2027. Enrollment is estimated at 1800 participants, and the primary outcome is Number of Participants With Adverse Events (AEs) over up to approximately 2 years1.
- Hoffmann-La Roche is recruiting for a Phase I study of RO7821657, a CEACAM5-targeted antibody, in people with locally advanced or metastatic solid tumors, with an actual start date of November 10, 2026. The study aims to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics, and evaluate pharmacodynamic and biomarker effects to support selection of recommended Phase 2 doses2, with Part 1 enrolling participants with microsatellite-stable colorectal cancer and Part 2 evaluating RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer2.
Fact check notes
- Sentence removed
The study is designed to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
copied source wording - Sentence removed
Enrollment is estimated at 405 participants.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.